Clay Siegall: The Zealous Cancer Therapies Researcher

Cancer as globally known as the world’s leading chronic killer disease. To date, curative treatments are yet to be formulated. However, medical researchers and scientists have not relented. They are still determined to fight off this enormous medical giant from the lives of people. Fortunately, these very skilled experts have been able to formulate various therapies and treatments that can curtail the spread, development, and also the effects of this killer disease. In the front line of this battle are Dr. Clay Siegall and Seattle Genetics.


Dr. Clay Siegall is the founder and current CEO of Seattle Genetics, a biotech firm that majors in the development of targeted therapy drugs for cancer. The company is located in Seattle. The respected scientist holds a Bachelor of Science in Zoology from the University of Maryland. More so, he has a Ph.D. in Genetics from the University of George Washington.


Dr. Clay Siegall explains that his career choice was prompted by the fact that medicine always fascinated him. With the new technologies, the idea interested him the more, and he wanted to personally experience the power and might of the advanced technology and reason to suppress the dominance of diseases in the world.


He continues to say that his interest became more real while pursuing his higher education. At that moment, his father fell sick and was diagnosed with cancer. The available treatment at the time was brutal such that he almost succumbed to death, not because of the ailment but the adverse effects of the chemotherapy treatment. In an effort to discover other treatment options, Clay’s desire was hatched, and he went ahead to base his career on it.


Dr. Clay Siegall explains how his company makes money. For starters, the firm sells its proprietary drugs, mostly the ADC. Besides, it reaps substantial revenues from production partnerships and licensing of technologies and processes. He explains that the entity has had its handful of struggles especially with capital issues but has since been resolved, and its operations have never ceased.


Dr. Clay Siegall has spanned a successful career with Seattle Genetics but has also served in other respectable institutions. He has worked at Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and also the National Institute of Health. Besides, he serves on the Board of Directors of Alder Bio-pharmaceuticals, and he has also authored over 70 scientific journals and is a holder of 15 patents. Dr. Siegall attributes his success to hard work, great focus, and passion.